Inventor · disambiguated record
Tara Arvedson
Also filed as: ARVEDSON TARA
6 granted patents·10 pending applications·32 citations·filing 2008–2023
80Inventor score
Top patents by PatentIndex Score
16 records- 0191US11692031B2Antibody constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jul 4, 2023·6 cites·18 claims
- 0286US10597456B2Chimeric receptors and methods of use thereofKITE PHARMA INC·Filed 2017·Granted Mar 24, 2020·6 cites·46 claims
- 0384US8629250B2Hepcidin, hepcidin antagonists and methods of useSASU BARBRA·Filed 2008·Granted Jan 14, 2014·14 cites·15 claims
- 0477US9175078B2Ferroportin antibodies and methods of useARVEDSON TARA·Filed 2009·Granted Nov 3, 2015·6 cites·53 claims
- 0573US2023331855A1Chimeric receptors and methods of use thereofKITE PHARMA INC·Filed 2023·Application pending·0 cites
- 0670US2024174745A1Antibody Constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 0766US2023124464A1Chimeric receptors to flt3 and methods of use thereofAMGEN INC·Filed 2022·Application pending·0 cites
- 0864US2020115457A1Chimeric receptors and methods of use thereofKITE PHARMA INC·Filed 2019·Application pending·0 cites
- 0961US2025282869A1Heteromultimer binding dll3 and cd3AMGEN INC·Filed 2023·Application pending·0 cites
- 1054US2014286953A1Hepcidin, hepcidin antagonists and methods of useAMGEN INC·Filed 2013·Application pending·0 cites
- 1150US2023146593A1Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitorAMGEN INC·Filed 2021·Application pending·0 cites
- 1247US12258404B2Bispecific antibody construct directed to MUC17 and CD3AMGEN INC·Filed 2018·Granted Mar 25, 2025·0 cites·19 claims
- 1347US2022403035A1Multitargeting antigen-binding molecules for use in proliferative diseasesAMGEN RES MUNICH GMBH·Filed 2020·Application pending·0 cites
- 1447US2023093169A1Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereofAMGEN RES MUNCH GMBH·Filed 2021·Application pending·0 cites
- 1546US9688759B2Ferroportin antibodies and methods of useAMGEN INC·Filed 2015·Granted Jun 27, 2017·0 cites·12 claims
- 1633US2013121959A1Il-22-fc and hepcidin activityMAXWELL JOSEPH R·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →